ImmuPharma (LON:IMM) Shares Up 28.6% - What's Next?

Key Points

• ImmuPharma shares surged by 28.6%, reaching a high of GBX 12 ($0.16) during mid-day trading, with a remarkable trading volume increase of 97% from average sessions.
• The company's market cap stands at £56.47 million, with a negative price-to-earnings ratio of -1,269.66, indicating significant financial challenges.
• ImmuPharma specializes in developing peptide-based therapeutics, including its lead program, P140 (Lupuzor™), targeted at treating autoimmune diseases such as Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shot up 28.6% during mid-day trading on Tuesday . The stock traded as high as GBX 12 ($0.16) and last traded at GBX 11.30 ($0.15). 17,007,168 shares were traded during trading, an increase of 97% from the average session volume of 8,614,648 shares. The stock had previously closed at GBX 8.79 ($0.12).

ImmuPharma Stock Performance

The company has a 50-day simple moving average of GBX 5.30 and a 200-day simple moving average of GBX 3.58. The company has a market cap of £56.47 million, a price-to-earnings ratio of -1,269.66 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, equities research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.